BioHarvest Sciences Inc. CNVCF BHSC 8MV revealed the detailed analysis of the composition of one of its Bio CELLicitation based cannabis products that were grown from a CBD Hemp plant. The analysis is derived from using industry standard HPLC measurements conducted by an independent third-party analytical laboratory which is ISO17025 cGMP accredited and is certified by the Israeli Ministry of Health.
In addition to the cannabinoids described in the table above, the β-caryophyllene, Beta-panasinsene and selina terpenes were present in the composition.
Increasing the total cannabinoids from 3% in the original plant flower to 36% and increasing THC from 0.09% to 7.5% in the final product (83X) demonstrate the power of BHSC's Bio-Plant CELLicitation technology to control the cannabinoids levels and ratios in a full spectrum composition.
The ability to start from a CBD Hemp plant and control the THC levels in the final composition would allow BioHarvest to sell unique Hemp-based non-synthetic therapeutic products on a federally legal base in the US. The sales & marketing of such products will take advantage of the already established "Direct to Consumer" commercial platform successfully employed by BioHarvest for its VINIA product. BioHarvest can also target a wider range of health and wellness applications with products that combine its Polyphenols-based compounds with the hemp-based compositions.
Ilan Sobel, CEO, stated "The ability to produce unique cannabis and hemp based compositions gives us tremendous flexibility to decide which markets to pursue, what would be the optimal products offerings and partnerships. In addition, the high level of Cannabinoids, combined with our unique cost advantage opens the door for the production of distillates and isolates of specific cannabinoids resulting in multiple levers to optimize revenue and profitability from this vertical."
Photo: Courtesy of BioHarvest Sciences Inc.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.